Praxis Precision Medicines (PRAX) Competitors $40.45 +2.74 (+7.27%) Closing price 04:00 PM EasternExtended Trading$40.48 +0.02 (+0.06%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. MIRM, MLTX, MTSR, PTGX, AAPG, LNTH, AKRO, APLS, ZLAB, and CRNXShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), Akero Therapeutics (AKRO), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Mirum Pharmaceuticals MoonLake Immunotherapeutics Metsera Protagonist Therapeutics Ascentage Pharma Group International Lantheus Akero Therapeutics Apellis Pharmaceuticals Zai Lab Crinetics Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Which has better valuation and earnings, MIRM or PRAX? Mirum Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M11.06-$87.94M-$1.21-61.31Praxis Precision Medicines$8.55M99.59-$182.82M-$12.29-3.29 Does the media prefer MIRM or PRAX? In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 13 mentions for Mirum Pharmaceuticals and 8 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.05 beat Mirum Pharmaceuticals' score of 0.48 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in MIRM or PRAX? 67.8% of Praxis Precision Medicines shares are held by institutional investors. 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer MIRM or PRAX? Mirum Pharmaceuticals currently has a consensus target price of $74.44, indicating a potential upside of 0.34%. Praxis Precision Medicines has a consensus target price of $85.88, indicating a potential upside of 112.30%. Given Praxis Precision Medicines' higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more volatility and risk, MIRM or PRAX? Mirum Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500. Is MIRM or PRAX more profitable? Mirum Pharmaceuticals has a net margin of -13.65% compared to Praxis Precision Medicines' net margin of -2,137.48%. Mirum Pharmaceuticals' return on equity of -24.76% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-13.65% -24.76% -8.50% Praxis Precision Medicines -2,137.48%-60.07%-54.84% SummaryMirum Pharmaceuticals beats Praxis Precision Medicines on 9 of the 15 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$793.67M$3.15B$5.79B$10.18BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-3.2921.2474.8626.40Price / Sales99.59464.25543.29125.95Price / CashN/A44.4425.8129.91Price / Book1.699.6413.256.28Net Income-$182.82M-$53.20M$3.29B$270.38M7 Day Performance-0.74%0.44%0.47%2.70%1 Month Performance-14.08%4.26%4.60%5.99%1 Year Performance-32.45%9.43%73.42%25.94% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines2.4635 of 5 stars$40.45+7.3%$85.88+112.3%-37.0%$793.67M$8.55M-3.29110Positive NewsMIRMMirum Pharmaceuticals3.3134 of 5 stars$77.39+1.7%$74.13-4.2%+80.7%$3.82B$336.89M-63.96140Analyst ForecastInsider TradeMLTXMoonLake Immunotherapeutics2.5081 of 5 stars$61.12+2.8%$74.43+21.8%+2.9%$3.82BN/A-21.992MTSRMetseraN/A$35.10-2.1%$59.00+68.1%N/A$3.77BN/A0.0081Analyst UpgradePTGXProtagonist Therapeutics2.3559 of 5 stars$56.19-7.2%$67.20+19.6%+25.2%$3.77B$434.43M80.27120News CoveragePositive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$41.04+1.3%N/AN/A$3.76B$134.35M0.00600Positive NewsHigh Trading VolumeLNTHLantheus4.5389 of 5 stars$53.63-2.0%$91.60+70.8%-49.8%$3.72B$1.53B14.26700Trending NewsAnalyst ForecastAKROAkero Therapeutics3.8912 of 5 stars$44.57-0.3%$81.14+82.1%+59.0%$3.58BN/A-22.2930Positive NewsAnalyst DowngradeInsider TradeAPLSApellis Pharmaceuticals4.2974 of 5 stars$26.91-4.3%$34.12+26.8%-33.9%$3.55B$781.37M-14.79770ZLABZai Lab3.0812 of 5 stars$31.33+1.9%$56.35+79.9%+59.9%$3.44B$398.99M-15.361,869Insider TradeGap UpHigh Trading VolumeCRNXCrinetics Pharmaceuticals3.6504 of 5 stars$35.14-1.3%$68.86+96.0%-36.8%$3.35B$1.04M-8.55210Positive News Related Companies and Tools Related Companies Mirum Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Metsera Competitors Protagonist Therapeutics Competitors Ascentage Pharma Group International Competitors Lantheus Competitors Akero Therapeutics Competitors Apellis Pharmaceuticals Competitors Zai Lab Competitors Crinetics Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
